Latest Regulatory Milestones News

Estrella Resources has ramped up its manganese exploration at the Ira Miri Project in Timor-Leste with a more powerful diamond drill rig and a fresh supergene manganese outcrop discovery, setting the stage for an extensive drilling program.

Sumitomo Corporation's subsidiary has gained crucial Foreign Investment Review Board approval to invest in Tivan Limited's Speewah Fluorite Project, paving the way for a significant joint venture.

EVE Health Group’s subsidiary Nextract has inked a pivotal two-year agreement with TeleDocs Clinic, enabling nationwide online prescribing of its upcoming erectile dysfunction and dysmenorrhea products ahead of regulatory approval.

Bubs Australia has submitted critical clinical trial data to the US FDA, marking a pivotal step toward permanent approval for its infant formulas in the US market.

Syntara Limited has unveiled encouraging interim Phase 2a data for SNT-5505, an add-on therapy targeting myelofibrosis patients with suboptimal response to ruxolitinib. The data highlight meaningful symptom relief and spleen volume reduction, positioning the drug as a potential game-changer in a challenging treatment landscape.

Renascor Resources has received provisional development authorisation from South Australia’s Minister for Planning to build a commercial-scale battery anode material plant, marking a pivotal step in its vertically integrated graphite project.

PointsBet Holdings has secured Foreign Investment Review Board approval for MIXI Australia's proposed full acquisition, marking a key regulatory milestone in the takeover process.

Southern Palladium has raised A$8 million through a strategic placement to accelerate its Definitive Feasibility Study and staged mine development at the Bengwenyama PGM project, backed by a major cornerstone investor.

Pure Hydrogen Corporation has secured a 15-year Potential Commercial Area approval and extended its ATP 927 permit for the Windorah Gas Project, marking a critical regulatory milestone ahead of its planned spinout.

Syntara Limited’s lead drug candidate SNT-5505 has secured FDA Fast Track designation, expediting its development for treating myelofibrosis, a rare and serious blood cancer with limited therapies.

Lotus Resources has secured Environmental and Social Impact Assessment approval for its Kayelekera Uranium Project in Malawi, paving the way for uranium production to resume in the third quarter of 2025. The company also completed a key board transition, signaling a new phase in its governance.

Chimeric Therapeutics has secured FDA Fast Track designation for its CHM CDH17 CAR-T therapy targeting gastroenteropancreatic neuroendocrine tumours, accelerating its path toward regulatory approval and patient access.